Analytical Data
-
Gene name
ACVR1
-
简介
Activin A receptor, type I (ACVR1), also known as ALK-2, is a bone morphogenetic protein (BMP) type I receptor. ACVR1 is involved in a wide variety of biological processes, including bone, heart, cartilage, nervous, and reproductive system development and regulation[1]. ACVR1 Protein, Mouse (HEK293, His-hFc) is produced in HEK293 cells with a C-Terminal His-tag and a C-Terminal Fc-tag . It consists of 123 amino acids (M1-E123).
- Application
-
Alternative Names
Activin receptor type-1; ACTR-I; SKR1; TSR-I; TSK-7L; Acvrlk2; Tgfb1
-
Species
Mouse
-
Source
HEK293
-
Tag
C-hFc;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P37172
-
Expression Region
M1-E123
-
Protein Length
Extracellular Domain
-
Molecular Weight
45 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ACVR1, also known as Activin A receptor type 1, is a member of the transforming growth factor-beta (TGF-β) superfamily, which plays a critical role in various cellular processes, including differentiation, proliferation, and apoptosis. Mutations in the ACVR1 gene have been implicated in several disorders, most notably Fibrodysplasia Ossificans Progressiva (FOP), a rare genetic condition characterized by abnormal bone formation in soft tissues. The study of ACVR1 recombinant protein is crucial for understanding the mechanisms underlying these pathological processes and for developing potential therapeutic interventions. By producing and characterizing ACVR1 recombinant proteins, researchers can explore the receptor's signaling pathways and its interactions with ligands, thereby elucidating how mutations alter its function and contribute to disease. Moreover, recombinant ACVR1 proteins serve as valuable tools in drug discovery and biomarker development, providing insights into targeted therapies for FOP and other related disorders. Understanding the structural and functional aspects of ACVR1 will pave the way for innovative treatments that could improve patient outcomes in conditions associated with aberrant bone growth and tissue remodeling.
